低级别蛋白尿不能预测狼疮性肾炎的良好结局:一项纵向队列研究
该研究对239例经活检证实的狼疮性肾炎患者按基线24小时尿蛋白(<1 g/24 h vs ≥1 g/24 h)分层,比较两组临床特征、肾脏病理治疗反应及肾脏结局。结果显示低级别蛋白尿组与高级别蛋白尿组在26周和52周的总体肾脏缓解率相似,且156周内eGFR下降30%或40%的风险概率相当。在复发性狼疮性肾炎中,肾小球硬化可独立预测长期肾功能恶化。
要点
- 低级别蛋白尿(UPro <1 g/24 h)的狼疮性肾炎患者肾脏结局和治疗反应并不优于高级别蛋白尿患者。
- 两组在26周和52周的总体肾脏缓解率相似,156周内eGFR下降30%或40%的风险概率相当。
- 肾小球硬化可独立预测复发性狼疮性肾炎的长期肾功能恶化,但对初发狼疮性肾炎无此预测作用。
核心结论
- 低级别蛋白尿(UPro <1 g/24 h)不能为狼疮性肾炎带来更好的肾脏结局或治疗反应。
- 肾小球硬化可预测复发性狼疮性肾炎的肾功能下降。
研究设计与样本
- 纵向队列研究,纳入239例经活检证实的狼疮性肾炎患者。
- 按基线24小时尿蛋白水平(<1 g/24 h vs ≥1 g/24 h)和疾病起病状态(初发 vs 复发)分层。
- 采用Cox比例风险回归和Kaplan-Meier分析评估156周内首次eGFR下降30%和40%的预测因素。
主要发现
- 239例患者中42例(17.6%)UPro <1 g/24 h,197例(82.4%)UPro ≥1 g/24 h;122例(51.0%)为初发狼疮性肾炎,117例(49.0%)为复发性狼疮性肾炎。
- UPro <1组较UPro ≥1组尿沉渣发生率更低、V型比例更高、肾脏病理活动指数更低,但慢性指数相似。
- 两组在26周和52周的总体肾脏缓解率相似。
- 低级别蛋白尿患者与高级别蛋白尿患者在156周内eGFR下降30%或40的风险概率相当。
- 肾小球硬化可独立预测复发性狼疮性肾炎的长期肾功能恶化,但对初发狼疮性肾炎无此预测作用。
关键数值与推荐
- 基线24小时尿蛋白分层阈值:<1 g/24 h vs ≥1 g/24 h。
- 肾脏治疗反应评估时间点:第26周和第52周。
- 肾脏结局评估:156周内eGFR下降30%和40%。
临床怎么用
- 低级别蛋白尿(UPro <1 g/24 h)不应被视为狼疮性肾炎预后良好的指标。
- 结果强调早期活检、个体化治疗和密切监测的重要性,并支持使用无创生物标志物进行风险评估。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the clinical characteristics, renal pathology treatment responses, and renal outcomes of patients with lupus nephritis (LN) with different levels of baseline proteinuria. METHODS: A total of 239 patients with biopsy-proven LN were stratified by baseline 24-h urine protein (UPro) levels (<1 g/24 h vs ≥1 g/24 h) and disease onset status (incident vs relapsing). Renal treatment responses were measured by overall renal response, complete response, and primary efficacy renal response at weeks 26 and 52. Cox proportional hazards regression and Kaplan-Meier analyses were used to assess predictors of time to first 30% and 40% estimated glomerular filtration rate (eGFR) decline by 156 weeks. RESULTS: Among the 239 patients with LN, 42 (17.6%) had UPro <1 g/24 h, and 197 (82.4%) had UPro ≥1 g/24 h; 122 (51.0%) had incident LN and 117 (49.0%) had relapsing LN. The UPro <1 group had a lower incidence of urinary sediments, a higher frequency of class V, and a lower renal pathology activity index but similar chronicity index compared with the UPro ≥1 group. Both groups exhibited similar overall renal response rates at weeks 26 and 52. Patients with low-grade proteinuria had equivalent risk probabilities for experiencing a 30% or 40% decline in eGFR over 156 weeks compared with those with high-grade proteinuria. Glomerulosclerosis independently predicted long-term renal deterioration in relapsing but not incident LN. CONCLUSION: Low-grade proteinuria (UPro <1g/24h) does not confer better renal outcomes or treatment response in LN. Glomerulosclerosis predicts renal function decline in relapsing LN. These results underscore the importance of early biopsy, personalized therapy, and close monitoring, supported by noninvasive biomarkers for risk assessment.
引用
- Shen Y, Peng J, Dai D, et al. Low-Grade Proteinuria Does Not Predict Favorable Outcomes in Lupus Nephritis: A Longitudinal Cohort Study. Arthritis Rheumatol. 2026. PMID: 41312658. doi:10.1002/art.70009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。